C
아미노로직스
074430KOSDAQ49.0 / 100
Reference Date: 2026-10-23
Financial Score19.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.5% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
AmiNoLogics primarily engages in the manufacturing and sales of raw pharmaceutical materials and amino acid derivative compounds, supplying treatments for conditions such as stroke, eye diseases, and dermatitis to domestic pharmaceutical companies. The pharmaceutical industry operates under strict government regulations, intense competition, and a focus on generic drug development.
Number of Employees
41people
Average Salary
69.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
24.90Industry Average 15.001.5Point
1.7x industry avg (risky)
PBR
1.59Industry Average 1.202.5Point
Higher than industry avg (caution)
ROE
6.54Industry Average 8.002.5Point
Below industry avg
Debt Ratio
1.09Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲5.8% (2-year basis)
Operating Profit Growth Rate
2.0 / 3
Avg ▲9.8% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 2.7% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (13%, downtrend)
Current 996Won52-week high 1,83852-week low 863
1-month return3.0Point
1m -1.48% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral주식등의대량보유상황보고서(약식)2026-10-08
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02
- Neutral주식등의대량보유상황보고서(일반)2026-10-02